MRNA — candidate.roundup

Update

MRNA — candidate.roundup

Reason: MRNA cooled this cycle rather than extending further - 30D down to +126.12% (was +158.71%), 1-year change +467.03% (was +499.46%), alpha +450.82 (was +480.81) - still the desk's most extreme number, magnitude still unaccounted for by any on-file receipt. AMGN deteriorated sharply: RSI fell to 31.5 (was 62.5, now near-oversold), 7D -13.7%, 1-year change down to +33.47% (was +56.1%), alpha to +17.25 (was +37.45), and its cushion above its 200-day thinned to +5% (was +23.4%). VRTX cooled across every window (1-year change +29.71%, was +37.59%). TMO held roughly steady.

Price/RSI Table

Stock Price 7D 30D 52wkHi RSI Status Action
MRNA $143.97 -1.09% +126.12% -18.50% 61.2 🟢 Extended 🔍 Watch/Research
VRTX $515.44 -5.62% -1.96% -8.00% 44.0 🟢 Pullback entry 🔒 Hold
TMO $609.82 -0.65% +1.13% -5.75% 54.8 🟢 Pullback entry 🔒 Hold
AMGN $377.35 -13.70% -9.33% -15.59% 31.5 🟡 Neutral 🔍 Watch

What Changed Since 2026-09-04

  • MRNA cooled rather than extending: 30D +126.12% (was +158.71%), 1-year change +467.03% (was +499.46%), alpha +450.82 (was +480.81) - still the sharpest number on the desk. No fresher news receipt was pulled this cycle beyond the previously-noted litigation-settlement item; the magnitude remains unaccounted for.
  • AMGN is this cycle's new deterioration: RSI fell from 62.5 to 31.5 (near-oversold), 7D -13.7%, 1-year change down to +33.47% (was +56.1%), alpha to +17.25 (was +37.45), and its 200-day cushion thinned to +5% (was +23.4%). AMGN's own news receipt is fetched 2026-09-09 (one day short of this cycle's freshness bar) and lists a 2026-09-09 headline referencing Amgen dropping pipeline candidate AMG 513 alongside Q2 results - noted but not treated as a confirmed cause here since the receipt predates the required window; research/stock-events shows no dated event this week for AMGN. Cause otherwise unknown for the week's decline.
  • VRTX cooled across every window: 1-year change +29.71% (was +37.59%), alpha +13.49 (was +18.93).
  • TMO held roughly steady: 1-year change +24.1% (was +25.39%), alpha +7.88 (was +6.74, essentially flat).

Sources

  • Tape data (price/RSI/SMA/returns/1-year change/1-year alpha): pre-computed summaries as of the 2026-09-11 close — biotech (MRNA, VRTX, TMO) and biotech-scan (AMGN, tracked outside the core biotech watchlist).
  • News check (AMGN): latest (fetched 2026-09-09, one day short of this cycle's freshness bar; no fresher pull found).
  • Prior-cycle comparison: 2026-09-04-biotech.
10 events

No direct external sources are attached to this read.